Fax: (011) 39 0516364037
Hairy cell leukemia
Evaluation of the long-term outcome in 121 patients
Version of Record online: 1 JUL 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 20, pages 4788–4792, 15 October 2010
How to Cite
Zinzani, P. L., Pellegrini, C., Stefoni, V., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S. and Baccarani, M. (2010), Hairy cell leukemia. Cancer, 116: 4788–4792. doi: 10.1002/cncr.25243
- Issue online: 1 JUL 2010
- Version of Record online: 1 JUL 2010
- Manuscript Accepted: 29 DEC 2009
- Manuscript Revised: 10 NOV 2009
- Manuscript Received: 29 AUG 2009
- hairy cell leukemia;
Historically, the first treatment choices for hairy cell leukemia (HCL) were splenectomy and alpha-interferon. Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients.
The authors analyzed the outcome of different lines of therapy in 121 HCL patients followed in their institute from 1986 to 2008, with a median follow-up of 105 months. Patients were divided into subgroups according to the number of treatments; Group A included 121 patients who underwent a front-line therapy, Group B patients (n =53) were treated with 2 lines, Group C patients (n = 34) with 3 lines, Group D patients (n = 17) with 4 lines, and Group E patients (n = 8) with 5 lines.
In Group A, 92 (77%) patients obtained a complete response (CR), 23 (18%) a partial response, and the remaining 6 (5%) a minor or no response; median duration of response was 2.7 years. In Group B, 53 relapsed patients achieved a second CR rate of 73.5%; median duration of response was 2.5 years. Group C contained 34 patients in a second relapse, with a CR rate after the third line of treatment of 70.5% (median duration of response, 2.2 years). In Group D, 11 (64.7%) patients obtained a CR (median duration of response, 1.6 years), and in Group E 4 (50%) of 8 patients achieved a CR (median duration of response, 1.3 years).
This study confirms the high risk (>40% of all patients) of retreatment of HCL patients and the need to maximize primary response. Cancer 2010. © 2010 American Cancer Society.